Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. More Details
Excellent balance sheet with limited growth.
Share Price & News
How has AlloVir's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ALVR is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.
Volatility Over Time: Insufficient data to determine ALVR's volatility change over the past year.
7 Day Return
1 Year Return
Return vs Industry: Insufficient data to determine how ALVR performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how ALVR performed against the US Market.
Long-Term Price Volatility Vs. Market
How volatile is AlloVir's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StIs AlloVir, Inc.'s (NASDAQ:ALVR) Shareholder Ownership Skewed Towards Insiders?
1 month ago | Simply Wall StWe Think AlloVir (NASDAQ:ALVR) Can Afford To Drive Business Growth
2 months ago | Simply Wall StHow Much Are AlloVir, Inc. (NASDAQ:ALVR) Insiders Spending On Buying Shares?
Is AlloVir undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: ALVR ($42.69) is trading above our estimate of fair value ($13.52)
Significantly Below Fair Value: ALVR is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: ALVR is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: ALVR is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ALVR's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ALVR is overvalued based on its PB Ratio (7x) compared to the US Biotechs industry average (4.4x).
How is AlloVir forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ALVR is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ALVR is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ALVR is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ALVR's revenue (64.9% per year) is forecast to grow faster than the US market (10.6% per year).
High Growth Revenue: ALVR's revenue (64.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ALVR is forecast to be unprofitable in 3 years.
How has AlloVir performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: ALVR is currently unprofitable.
Growing Profit Margin: ALVR is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if ALVR's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare ALVR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ALVR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-10.3%).
Return on Equity
High ROE: ALVR has a negative Return on Equity (-14.26%), as it is currently unprofitable.
How is AlloVir's financial position?
Financial Position Analysis
Short Term Liabilities: ALVR's short term assets ($383.9M) exceed its short term liabilities ($13.5M).
Long Term Liabilities: ALVR's short term assets ($383.9M) exceed its long term liabilities ($6.3M).
Debt to Equity History and Analysis
Debt Level: ALVR is debt free.
Reducing Debt: ALVR has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ALVR has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if ALVR has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is AlloVir current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ALVR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ALVR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ALVR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ALVR's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ALVR's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
David Hallal (54 yo)
Mr. David L. Hallal serves as Lead Independent Director of Seer Biosciences, Inc. since September 2020. Mr. Hallal serves as a Director of Seer Biosciences, Inc. since February 2018. Mr. Hallal is Chairman...
CEO Compensation Analysis
Compensation vs Market: David's total compensation ($USD3.57M) is about average for companies of similar size in the US market ($USD5.01M).
Compensation vs Earnings: Insufficient data to compare David's compensation with company performance.
|Chairman & CEO||2.33yrs||US$3.57m||5.2% |
|President||no data||US$1.63m||1.31% |
|Chief Medical Officer & Head of Global Medical Sciences||1.75yrs||US$2.18m||0.86% |
|Chief Accounting Officer||2yrs||no data||0.088% |
|Chief Scientific Officer||8yrs||no data||4.05% |
|General Counsel||2yrs||no data||0.59% |
|Chief Commercial Officer||2yrs||no data||0.85% |
|Head & GM of Europe and Middle East Operations||0.75yr||no data||no data|
|Chief Regulatory & Safety Officer||0.50yr||no data||0.13% |
|Senior Vice President of Technical Operations||1yr||no data||no data|
Experienced Management: ALVR's management team is considered experienced (2 years average tenure).
|Chairman & CEO||2.33yrs||US$3.57m||5.2% |
|President||no data||US$1.63m||1.31% |
|Independent Non-Executive Director||2.33yrs||US$130.90k||0.049% |
|Independent Non-Executive Director||9yrs||US$125.90k||0.049% |
|Independent Non-Executive Director||0.50yr||no data||0.082% |
|Independent Non-Executive Director||1.67yrs||US$117.15k||8.09% |
|Independent Non-Executive Director||3yrs||US$130.90k||5.21% |
|Independent Non-Executive Director||0.50yr||no data||0.010% |
|Non-Executive Director||no data||US$240.90k||4% |
Experienced Board: ALVR's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: ALVR only recently listed within the past 12 months.
AlloVir, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: AlloVir, Inc.
- Ticker: ALVR
- Exchange: NasdaqGS
- Founded: 2013
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$2.632b
- Shares outstanding: 61.66m
- Website: https://www.allovir.com
Number of Employees
- AlloVir, Inc.
- 139 Main Street
- Suite 500
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ALVR||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Jul 2020|
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/01/23 00:06|
|End of Day Share Price||2021/01/22 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.